علاج الالتهاب الرئوي بـ Moraxella catarrhalis لدى المرضى البالغين المستشفيين بالتهاب رئوي مجتمعي شديد

DOI: 10.1164/rccm.201908-1581ST

• In inpatient adults with severe CAP (see Table 1) without risk factors for MRSA or P. aeruginosa, we recommend (Table 4) (note, specific agents and doses are the same as 9.1):
• a β-lactam plus a macrolide (strong recommendation, moderate quality of evidence); or
• a β-lactam plus a respiratory fluoroquinolone (strong recommendation, low quality of evidence).
• A variety of criteria for determining clinical improvement have been developed for patients with CAP and validated in clinical trials, including resolution of vital sign abnormalities (heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature), ability to eat, and normal mentation.
• As most patients will achieve clinical stability within the first 48 to 72 hours, a total duration of therapy of 5 days will be appropriate for most patients.